183 related articles for article (PubMed ID: 8592603)
1. Type I procollagen propeptide in patients on CAPD: its relationships with bone histology, osteocalcin, and parathyroid hormone.
Joffe P; Heaf JG; Jensen LT
Nephrol Dial Transplant; 1995 Oct; 10(10):1912-7. PubMed ID: 8592603
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of carboxy-terminal propeptide of type I procollagen in pediatric patients undergoing peritoneal dialysis.
Leszczynska B; Roszkowska-Blaim M
Adv Perit Dial; 2002; 18():2-5. PubMed ID: 12402576
[TBL] [Abstract][Full Text] [Related]
3. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
4. Osteocalcin: a non-invasive index of metabolic bone disease in patients treated by CAPD.
Joffe P; Heaf JG; Hyldstrup L
Kidney Int; 1994 Sep; 46(3):838-46. PubMed ID: 7996805
[TBL] [Abstract][Full Text] [Related]
5. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
Francini G; Gonnelli S; Petrioli R; Bruni S; Marsili S; Aquino A; Camporeale A
Cancer Epidemiol Biomarkers Prev; 1993; 2(2):125-9. PubMed ID: 8467247
[TBL] [Abstract][Full Text] [Related]
6. Type I and III procollagens in CAPD: markers of peritoneal fibrosis.
Joffe P; Jensen LT
Adv Perit Dial; 1991; 7():158-60. PubMed ID: 1680415
[TBL] [Abstract][Full Text] [Related]
7. Procollagen type-I in the serum and dialysate of continuous ambulatory peritoneal dialysis patients.
Digenis GE; Dombros NV; Christophoraki M; Grapsa I; Savidis N; Datseris J; Samuilidou E; Zerefos N; Tourkantonis A
Perit Dial Int; 1993; 13 Suppl 2():S480-3. PubMed ID: 8399646
[TBL] [Abstract][Full Text] [Related]
8. Carboxy-terminal propeptide of human type I collagen and pyridinium cross-links as markers of bone growth in infants 1 to 18 months of age.
Lieuw-A-Fa M; Sierra RI; Specker BL
J Bone Miner Res; 1995 Jun; 10(6):849-53. PubMed ID: 7572307
[TBL] [Abstract][Full Text] [Related]
9. Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients.
Ureña P; Ferreira A; Kung VT; Morieux C; Simon P; Ang KS; Souberbielle JC; Segre GV; Drüeke TB; De Vernejoul MC
J Bone Miner Res; 1995 Jun; 10(6):932-9. PubMed ID: 7572317
[TBL] [Abstract][Full Text] [Related]
10. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure.
Franke S; Lehmann G; Abendroth K; Hein G; Stein G
Eur J Med Res; 1998 Feb; 3(1-2):81-8. PubMed ID: 9512973
[TBL] [Abstract][Full Text] [Related]
11. Increased serum levels of carboxyterminal propeptide of type 1 collagen (PICP) in hyperthyroidism.
Legovini P; De Menis E; Da Rin G; Roiter I; Breda F; Artuso V; Di Virgilio R; Conte N
Horm Metab Res; 1994 Jul; 26(7):334-7. PubMed ID: 7959610
[TBL] [Abstract][Full Text] [Related]
12. Twenty-four-hour osteocalcin, carboxyterminal propeptide of type I procollagen, and aminoterminal propeptide of type III procollagen rhythms in normal and growth-retarded children.
Saggese G; Baroncelli GI; Bertelloni S; Cinquanta L; DiNero G
Pediatr Res; 1994 Apr; 35(4 Pt 1):409-15. PubMed ID: 8047377
[TBL] [Abstract][Full Text] [Related]
13. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
14. Effects of short-term maximal work on plasma calcium, parathyroid hormone, osteocalcin and biochemical markers of collagen metabolism.
Kristoffersson A; Hultdin J; Holmlund I; Thorsen K; Lorentzon R
Int J Sports Med; 1995 Apr; 16(3):145-9. PubMed ID: 7649703
[TBL] [Abstract][Full Text] [Related]
15. [Serum levels of carboxyterminal propeptide of type I procollagen (PICP), cross-linked carboxyterminal telopeptide region of type I collagen (ICTP) and carboxyterminal parathyroid hormone-related protein (C-PTHrP) in hematological malignancies with bone lesions and hypercalcemia].
Tanaka K; Shiraishi K; Sakamoto A; Jojima H; Masuchi K; Okubo Y; Tanaka M; Fuzimatsu Y; Fukahori S; Osabe S; Imamura Y; Honda J; Oizumi K
Rinsho Ketsueki; 1998 Apr; 39(4):273-80. PubMed ID: 9597894
[TBL] [Abstract][Full Text] [Related]
16. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
[TBL] [Abstract][Full Text] [Related]
17. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
18. Clearance of osteocalcin in adults with end-stage renal disease undergoing CAPD.
Klein JR; Grunewald RW; Steffgen J; Franz HE
Adv Perit Dial; 1991; 7():225-9. PubMed ID: 1680431
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate kinetics in patients undergoing continuous ambulatory peritoneal dialysis: relations to dynamic bone histomorphometry, osteocalcin and parathyroid hormone.
Joffe P; Hyldstrup L; Heaf JG; Pødenphant J; Henriksen JH
Am J Nephrol; 1992; 12(6):419-24. PubMed ID: 1292341
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
